{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:51:46Z","timestamp":1776106306751,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clon.2026.104071","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:04:51Z","timestamp":1769875491000},"page":"104071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Unravelling Salvage Re-irradiation for Locally Recurrent Prostate Cancer: Challenges and Complexities"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-339X","authenticated-orcid":false,"given":"L.V.","family":"Biolatti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1495-9522","authenticated-orcid":false,"given":"N.","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8094-3232","authenticated-orcid":false,"given":"A.","family":"Devi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5325-3739","authenticated-orcid":false,"given":"J.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8572-044X","authenticated-orcid":false,"given":"C.W.","family":"Bleaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104071_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/cncr.23161","article-title":"Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes","volume":"112","author":"Agarwal","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2026.104071_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102206","article-title":"Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: an ESTRO ACROP Delphi consensus","volume":"98","author":"Jereczek-Fossa","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clon.2026.104071_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.681448","article-title":"Salvage reirradiation options for locally recurrent prostate cancer: a systematic review","volume":"11","author":"Zhong","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53799-7","article-title":"Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance","volume":"9","author":"Inder","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clon.2026.104071_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/mc.22913","article-title":"SMC1A is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties","volume":"58","author":"Yadav","year":"2019","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.clon.2026.104071_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.09.037","article-title":"The transcriptional landscape of radiation-treated human prostate cancer: analysis of a prospective tissue cohort","volume":"100","author":"Keam","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104071_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1470-2045(08)70076-7","article-title":"Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study","volume":"9","author":"Vergis","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ebiom.2018.04.019","article-title":"Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer","volume":"31","author":"Yang","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.clon.2026.104071_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clon.2026.104071_bib10","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2019.12.025","article-title":"miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA","volume":"473","author":"Ray","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clon.2026.104071_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2015.02.046","article-title":"A feedback regulation between miR-145 and DNA methyltransferase 3b in prostate cancer cell and their responses to irradiation","volume":"361","author":"Xue","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clon.2026.104071_bib12","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/0008-5472.CAN-14-1924","article-title":"Aldehyde Dehydrogenase Is Regulated by \u03b2-Catenin\/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells","volume":"75","author":"Cojoc","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2026.104071_bib13","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.7150\/thno.58655","article-title":"GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy","volume":"11","author":"Mukha","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.clon.2026.104071_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ijrobp.2009.06.014","article-title":"A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation","volume":"75","author":"Eschrich","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104071_bib15","first-page":"63","article-title":"Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs","volume":"2","author":"McDermott","year":"2017","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib16","doi-asserted-by":"crossref","first-page":"11081","DOI":"10.18632\/oncotarget.2404","article-title":"NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer","volume":"5","author":"Berlin","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.clon.2026.104071_bib17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.juro.2016.09.117","article-title":"Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18F) positron emission tomography\/computerized tomography imaging in the staging of biochemically recurrent prostate cancer","volume":"197","author":"Bach-Gansmo","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.clon.2026.104071_bib18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/diagnostics13030387","article-title":"The role of mpMRI in the assessment of prostate cancer recurrence using the PI-RR system: diagnostic accuracy and interobserver agreement in readers with different expertise","volume":"13","author":"Bergaglio","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.clon.2026.104071_bib19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PET\/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.clon.2026.104071_bib20","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(02)02411-1","article-title":"Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy","volume":"61","author":"Kane","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.clon.2026.104071_bib21","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1007\/s00259-022-05693-0","article-title":"Diagnostic accuracy of [18F]PSMA-1007 PET\/CT in biochemical recurrence of prostate cancer","volume":"49","author":"Mingels","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clon.2026.104071_bib22","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3390\/diagnostics12123176","article-title":"Recurrent prostate cancer diagnostics with 18F-PSMA-1007 PET\/CT: a systematic review of the current state","volume":"12","author":"Saule","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.clon.2026.104071_bib23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2967\/jnumed.120.246363","article-title":"Diagnostic accuracy of 18F-PSMA-1007 PET\/CT imaging for lymph node staging of prostate carcinoma in primary and biochemical recurrence","volume":"62","author":"Sprute","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clon.2026.104071_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1148\/radiol.2020191689","article-title":"PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis","volume":"296","author":"Tan","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.clon.2026.104071_bib25","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000481438","article-title":"Management of biochemical recurrence after primary curative treatment for prostate cancer: a review","volume":"100","author":"Artibani","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.clon.2026.104071_bib26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1148\/rg.2018170147","article-title":"Multiparametric MR imaging of the prostate after treatment of prostate cancer","volume":"38","author":"Patel","year":"2018","journal-title":"Radiographics"},{"key":"10.1016\/j.clon.2026.104071_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.973067","article-title":"Adaptive dose painting for prostate cancer","volume":"12","author":"Fred\u00e9n","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib28","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","article-title":"Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy","volume":"4","author":"Panebianco","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib29","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib30","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s00066-017-1239-1","article-title":"Oligometastases in prostate cancer: metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT","volume":"194","author":"Baumann","year":"2018","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clon.2026.104071_bib31","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1007\/s00259-022-05741-9","article-title":"Event-free survival after 68Ga-PSMA-11 PET\/CT in recurrent hormone-sensitive prostate cancer patients eligible for salvage therapy","volume":"49","author":"Ceci","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clon.2026.104071_bib32","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.118.221010","article-title":"Combination of 68Ga-PSMA PET\/CT and multiparametric MRI improves the detection of clinically significant prostate cancer: a lesion-by-lesion analysis","volume":"60","author":"Chen","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clon.2026.104071_bib33","first-page":"41","article-title":"Defining radio-recurrent intraprostatic target volumes using PSMA-targeted PET\/CT and multiparametric MRI","volume":"32","author":"Liu","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib34","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2026.104071_bib35","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2012.01.022","article-title":"Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature","volume":"61","author":"Chade","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2026.104071_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijrobp.2018.09.039","article-title":"A prospective phase II trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate cancer after external beam radiation therapy (NRG Oncology\/RTOG 0526)","volume":"103","author":"Crook","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104071_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109672","article-title":"Salvage prostate brachytherapy in radiorecurrent prostate cancer: an international Delphi consensus study","volume":"184","author":"Corkum","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib38","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijrobp.2019.10.014","article-title":"Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: efficacy and toxicity of HDR-like SBRT","volume":"106","author":"Fuller","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104071_bib39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13014-023-02271-y","article-title":"Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis","volume":"18","author":"Boldrini","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2020.01.023","article-title":"MRI-guided ultrafocal salvage high-dose-rate brachytherapy for localized radiorecurrent prostate cancer: updated results of 50 patients","volume":"107","author":"van Son","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104071_bib41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clon.2019.10.008","article-title":"Single-dose focal salvage high-dose-rate brachytherapy for locally recurrent prostate cancer","volume":"32","author":"Chitmanee","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clon.2026.104071_bib42","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ijrobp.2021.10.138","article-title":"Salvage low-dose-rate prostate brachytherapy: clinical outcomes of a phase II trial for local recurrence after external beam radiation therapy (NRG Oncology\/RTOG 0526)","volume":"112","author":"Crook","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104071_bib43","article-title":"MRI-guided focal or integrated boost high-dose-rate brachytherapy for recurrent prostate cancer","volume":"12","author":"M\u00e9nard","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109495","article-title":"Recurrence characteristics after focal salvage HDR brachytherapy in prostate cancer","volume":"180","author":"Rasing","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.radonc.2020.10.021","article-title":"Salvage low-dose-rate brachytherapy for prostate cancer recurrence following definitive external beam radiation therapy","volume":"155","author":"Smith","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib46","first-page":"1","article-title":"Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: a toxicity assessment of 150 patients","volume":"27","author":"van Son","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib47","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.adro.2020.04.022","article-title":"A novel salvage option for local failure in prostate cancer, reirradiation using external beam or stereotactic radiation therapy: systematic review and meta-analysis","volume":"5","author":"Corkum","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13014-017-0789-9","article-title":"Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy","volume":"12","author":"Mbeutcha","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.ijrobp.2019.07.012","article-title":"Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: a retrospective multicenter study of the GETUG","volume":"105","author":"Pasquier","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104071_bib50","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2020.07.014","article-title":"Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer","volume":"108","author":"Bergamin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104071_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026666","article-title":"GETUG-AFU 31: a phase I\/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol","volume":"9","author":"Pasquier","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.clon.2026.104071_bib52","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/biomedicines8120536","article-title":"68Ga-PSMA-11 PET\/CT-guided stereotactic body radiation therapy retreatment in prostate cancer patients with PSA failure after salvage radiotherapy","volume":"8","author":"Caroli","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.clon.2026.104071_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4149\/neo_2020_200622N651","article-title":"Partial prostate re-irradiation for the treatment of isolated local recurrence of prostate cancer in patients previously treated with primary external beam radiotherapy: short-term results of a monocentric study","volume":"68","author":"Matrone","year":"2021","journal-title":"Neoplasma"},{"key":"10.1016\/j.clon.2026.104071_bib54","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00066-020-01628-6","article-title":"Linac-based stereotactic body radiotherapy as a feasible salvage option for local recurrences in previously irradiated prostate cancer","volume":"196","author":"Cuccia","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clon.2026.104071_bib55","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.clon.2026.104071_bib56","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib57","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.euros.2020.06.006","article-title":"Genetic landscape of prostate cancer conspicuity on multiparametric magnetic resonance imaging: a systematic review and bioinformatic analysis","volume":"20","author":"Norris","year":"2020","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clon.2026.104071_bib58","doi-asserted-by":"crossref","first-page":"351","DOI":"10.21873\/anticanres.16170","article-title":"Exploring hypoxia in prostate cancer with T2-weighted magnetic resonance imaging radiomics and pimonidazole scoring","volume":"43","author":"Leech","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clon.2026.104071_bib59","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11547-023-01644-3","article-title":"Prediction of prostate tumour hypoxia using pre-treatment MRI-derived radiomics: preliminary findings","volume":"128","author":"Zhong","year":"2023","journal-title":"Radiol Med"},{"key":"10.1016\/j.clon.2026.104071_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-068580","article-title":"Protocol: Reirradiation options for previously irradiated prostate cancer (RO-PIP): feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy versus high-dose-rate brachytherapy","volume":"12","author":"Zhong","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.clon.2026.104071_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/srep34796","article-title":"Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells","volume":"6","author":"McDermott","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clon.2026.104071_bib62","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/emm.2005.74","article-title":"Radiosensitization by targeting radioresistance-related genes with protein kinase A inhibitor in radioresistant cancer cells","volume":"37","author":"Chin","year":"2005","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.clon.2026.104071_bib63","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1002\/pmic.200900523","article-title":"Chloride intracellular channel 1 identified using proteomic analysis plays an important role in the radiosensitivity of HEp-2 cells via reactive oxygen species production","volume":"10","author":"Kim","year":"2010","journal-title":"Proteomics"},{"key":"10.1016\/j.clon.2026.104071_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2017.10.018","article-title":"Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells - An updated review","volume":"362","author":"Muinao","year":"2018","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.clon.2026.104071_bib65","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","article-title":"Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study","volume":"82","author":"Arrayeh","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104071_bib66","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.3390\/jcm11195637","article-title":"Drivers of radioresistance in prostate cancer","volume":"11","author":"King","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clon.2026.104071_bib67","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1293::AID-CNCR11>3.0.CO;2-O","article-title":"p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy","volume":"85","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2026.104071_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118087","article-title":"Fractionated radiation promotes proliferation and radioresistance in bystander A549 cells but not in bystander HT29 cells","volume":"257","author":"Ghasemi","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.clon.2026.104071_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0360-3016(02)04468-1","article-title":"Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma compared with localized radio-na\u00efve prostate carcinoma","volume":"56","author":"Rosser","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104071_bib70","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/jrr\/rrab117","article-title":"STAT3 as a target for sensitizing prostate cancer cells to irradiation","volume":"63","author":"Zhang","year":"2022","journal-title":"J Radiat Res"},{"key":"10.1016\/j.clon.2026.104071_bib71","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.3390\/cancers14225504","article-title":"Radioresistance mechanisms in prostate cancer cell lines surviving ultra-hypo-fractionated EBRT: implications and possible clinical applications","volume":"14","author":"Sideri","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104071_bib72","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3390\/cancers16162839","article-title":"Potentiating salvage radiotherapy in radiorecurrent prostate cancer through anti-CTLA4 therapy: implications from a syngeneic model","volume":"16","author":"Wang","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104071_bib73","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3390\/biomedicines11061628","article-title":"Uncovering the Secrets of Prostate Cancer\u2019s Radiotherapy Resistance: Advances in Mechanism Research","volume":"11","author":"Lyu","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.clon.2026.104071_bib74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2026.104071_bib75","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2026.104071_bib76","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2026.104071_bib77","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2026.104071_bib78","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.22.01662","article-title":"Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial","volume":"41","author":"Tran","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib79","article-title":"Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care","volume":"35","author":"Moreno-Olmedo","year":"2025","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib80","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2967\/jnumed.117.202945","article-title":"Impact of 68Ga-PSMA-11 PET\/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clon.2026.104071_bib81","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fonc.2015.00090","article-title":"Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure","volume":"5","author":"Hu","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2026.104071_bib82","first-page":"5830","article-title":"Understanding the mechanism underlying the acquisition of radioresistance in human prostate cancer cells","volume":"17","author":"Murata","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.clon.2026.104071_bib83","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clon.2021.11.002","article-title":"Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous Postoperative or Definitive Radiotherapy: Long-term Results after a Median Follow-up of 4 Years","volume":"34","author":"Francolini","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clon.2026.104071_bib84","first-page":"20","article-title":"Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer","volume":"23","author":"Slevin","year":"2020","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526000427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T17:27:38Z","timestamp":1776101258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526000427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":84,"alternative-id":["S0936655526000427"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104071","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unravelling Salvage Re-irradiation for Locally Recurrent Prostate Cancer: Challenges and Complexities","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"104071"}}